Article ; Online: Briakinumab for the treatment of plaque psoriasis.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
2012 Volume 26, Issue 1, Page(s) 9–20
Abstract: Psoriasis is a chronic inflammatory skin disorder affecting approximately 2% of individuals worldwide. An improved understanding of the pathogenesis of psoriasis has led to the development of targeted biologic therapies. Briakinumab (ABT-874) is a ... ...
| Abstract | Psoriasis is a chronic inflammatory skin disorder affecting approximately 2% of individuals worldwide. An improved understanding of the pathogenesis of psoriasis has led to the development of targeted biologic therapies. Briakinumab (ABT-874) is a recombinant human antibody that blocks the biological activity of the cytokines interleukin (IL)-12 and IL-23 through their shared subunit p40. IL-12 and IL-23 are key mediators in T-cell differentiation and have been shown to play a significant role in maintaining inflammation and abnormal keratinocyte function in psoriasis patients through development and stimulation of Th1 and Th17 subsets, respectively. In one phase II and four phase III studies (including two 52-week trials), the Psoriasis Area and Severity Index (PASI)-75 score at weeks 12 and 52 was achieved by at least 80.6% and 66.2% (p < 0.001) of patients receiving more than one dose of briakinumab every 4 weeks, respectively, with high proportions of patients achieving PASI-90 and PASI-100 scores (at least 55.4% and 28.8%, respectively; p < 0.001). These studies indicate safety and tolerance of briakinumab therapy for patients with moderate-to-severe chronic plaque psoriasis. In one clinical trial, therapy was associated with increased incidence of major cardiac events. Available results from two briakinumab trials show its positive impact on health-related quality of life. However, the manufacturer has now withdrawn the application in the EU and US. |
|---|---|
| MeSH term(s) | Animals ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Clinical Trials as Topic/adverse effects ; Clinical Trials as Topic/statistics & numerical data ; Dermatologic Agents/adverse effects ; Dermatologic Agents/pharmacology ; Dermatologic Agents/therapeutic use ; Drug Approval ; Humans ; Interleukin-12/antagonists & inhibitors ; Interleukin-12/immunology ; Interleukin-23/antagonists & inhibitors ; Interleukin-23/immunology ; Psoriasis/drug therapy ; Psoriasis/immunology |
| Chemical Substances | Antibodies, Monoclonal ; Dermatologic Agents ; Interleukin-23 ; Interleukin-12 (187348-17-0) ; briakinumab (978I8M0P8X) |
| Language | English |
| Publishing date | 2012-02-01 |
| Publishing country | New Zealand |
| Document type | Journal Article ; Review |
| ZDB-ID | 1364202-9 |
| ISSN | 1179-190X ; 1173-8804 |
| ISSN (online) | 1179-190X |
| ISSN | 1173-8804 |
| DOI | 10.2165/11595940-000000000-00000 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 4112: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.